[A23-92] Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-92
Commission:
Commission awarded on 01.09.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Patients with achondroplasia 2 years of age and older whose epiphyses are not closed
Indication of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-92
| Project no. | Title | Status |
|---|---|---|
| G21-29 | Vosoritide (achondroplasia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A24-08 | Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92 | Commission completed |
| A23-116 | Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.